Navigation Links
For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
Date:4/20/2009

Percutaneous Coronary Intervention Will Retain Decision Resources' Clinical Gold Standard for Stable Angina, According to a New Report from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed cardiologists identify a therapy's effect on mortality as the attribute that most influences their prescribing decisions in coronary heart disease (stable angina). Clinical data and the opinions of interviewed thought leaders indicate that current and emerging therapies have no advantage in this attribute over carvedilol (GlaxoSmithKline's Coreg, generics), the sales-leading agent in the market.

The new report entitled Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality also finds that a therapy that reduces plaque volume more than Pfizer's Lipitor/Sortis/Tahor at 18 months would earn a 28 percent patient share in stable angina in the United States and a 37 percent patient share in Europe, according to surveyed U.S. and European cardiologists.

In 2008, Decision Resources' proprietary clinical gold standard for stable angina was percutaneous coronary intervention (PCI). Based on available data and expert opinion, PCI will retain gold-standard status for stable angina in 2012 as surveyed physicians believe it to be the most efficacious therapy for treating the symptoms of stable angina.

"Interestingly, surveyed physicians also indicate that Cardium Therapeutics' gene therapy Generx has great potential in treating stable angina," said Decision Resources Analyst Kate Sullivan, B.S. "However, experts we interviewed believe gene therapy is still at least 10 years away from becoming a viable therapeutic approach for the indication, which leaves PCI, over the next decade, as the most efficacious therapy for providing symptom relief to patients."

About the Report

Coronary Heart Disease (Stable Angina): To Gain Share, Emerging Therapies Must Not Only Control Symptoms but Also Reduce Mortality is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                         Decision Resources, Inc.
    Christopher Comfort                        Elizabeth Marshall
    781-296-2597                               781-296-2563
    ccomfort@dresources.com                    emarshall@dresources.com



'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Reducing Costs, Not Care: Medical Travel to New Zealand Can Help Alleviate Rising U.S. Healthcare Expenses for Insurers and Self-funded Employers
2. New Mexican health-care program successful at reducing crippling health care costs
3. Mexican health care program successful at reducing crippling health care costs
4. Angiogenesis inhibitor improves brain tumor survival by reducing edema
5. ADD-care -- A Natural, Homeopathic Alternative Reducing Symptoms Related to Attention Deficit Disorder
6. Employment Technologies Announces Pre-release of EASyView Virtual Interview System, Reducing Employer Time and Costs
7. Reducing suicidal behaviors among adolescents
8. Experts in Government, Public Health, Public Policy and Science Outline Blueprint for Reducing Death and Disease From Tobacco in the United States
9. Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma
10. The New Crystalens HD Gives Many Baby Boomers and Seniors an Opportunity to See Clearly at All Distances while Reducing or Eliminating the Need for Glasses
11. Effectiveness of Progesterone in Reducing Preterm Births May Be Altered by Genetic Predisposition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/25/2016)... Montreal, Canada (PRWEB) , ... June 25, 2016 , ... ... the pursuit of success. In terms of the latter, setting the bar too high ... low, risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: